Ask AI
ProCE Banner Activity

Redefining Success in Hepatitis B Care: FAQs

Clinical Thought

Read FAQs regarding the current state of HBV treatment and monitoring, including the shift toward earlier simplified treatment, functional cure, considerations for quantitative hepatitis B surface antigen monitoring, and HBV therapies in late stages of development.

Released: June 10, 2025

Expiration: June 09, 2026

Share

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

This educational activity is supported by an educational grant from GlaxoSmithKline.

GlaxoSmithKline

Faculty Disclosure

Primary Author

Jordan Feld, MD, MPH: consultant/advisor/speaker: AbbVie, GlaxoSmithKline, Pfizer, Precision Biosciences; researcher: AbbVie, Altimmune, Gilead, GlaxoSmithKline, Roche, Vir.

Norah Terrault, MD: researcher (paid to institution): Durect, Eiger, Genentech/Roche, GlaxoSmithKline, Immunocore.

Su Wang, MD, MPH, FACP: researcher (paid to institution): Gilead.